Literature DB >> 1287195

Models for describing absorption rate and estimating extent of bioavailability: application to cefetamet pivoxil.

N H Holford1, R J Ambros, K Stoeckel.   

Abstract

Five absorption rate models have been compared for describing cefetamet data in 34 adults after oral administration of cefetamet pivoxil with food alone or in combination with either an antacid or an H2 antagonist. A sequential zero- then first-order input process provided the most flexible description of the absorption rate of cefetamet. If the first-order rate constant is linked to the zero-order input parameters the model can be interpreted as the consequence of solubility-limited absorption. While a sequential input is theoretically reasonable to assume, the first-order process appeared to be independent of the zero-order input. A population-based approach was applied to estimate the effect of dose and gastric pH increase on absorption and disposition. There appeared to be a dose-associated change in several parameters. The most marked change was an increase in volume of distribution of cefetamet. Treatments expected to increase gastric pH slowed the first-order component of the absorption process. Three models for estimating the extent of bioavailability have been compared using observations from 18 adults and 13 children receiving iv cefetamet and oral cefetamet pivoxil on two separate occasions. The most consistent estimates of the disposition parameters and the extent of bioavailability were achieved with the sequential zero- and first-order model under the assumption that steady state volume of distribution and nonrenal clearance were the same after iv and oral treatment.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1287195     DOI: 10.1007/bf01061464

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  9 in total

1.  Theoretical model for both saturable rate and extent of absorption: simulations of cefatrizine data.

Authors:  W R Couet; B G Reigner; J P Guedes; T N Tozer
Journal:  J Pharmacokinet Biopharm       Date:  1991-06

2.  Saturable rate of cefatrizine absorption after oral administration to humans.

Authors:  B G Reigner; W Couet; J P Guedes; J B Fourtillan; T N Tozer
Journal:  J Pharmacokinet Biopharm       Date:  1990-02

3.  Gastrointestinal transit of a solid indigestible capsule as measured by radiotelemetry and dual gamma scintigraphy.

Authors:  P Mojaverian; K Chan; A Desai; V John
Journal:  Pharm Res       Date:  1989-08       Impact factor: 4.200

Review 4.  Pharmacokinetics of oral cefetamet pivoxil (Ro 15-8075) and intravenous cefetamet (Ro 15-8074) in humans: a review.

Authors:  K Stoeckel; Y K Tam; J Kneer
Journal:  Curr Med Res Opin       Date:  1989       Impact factor: 2.580

5.  Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in children.

Authors:  W L Hayton; R A Walstad; E Thurmann-Nielsen; T Kufaas; J Kneer; R J Ambros; H E Rugstad; E Monn; E Bodd; K Stoeckel
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

6.  Influence of antacid and ranitidine on the pharmacokinetics of oral cefetamet pivoxil.

Authors:  R A Blouin; J Kneer; R J Ambros; K Stoeckel
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

7.  Pharmacokinetics of cefetamet pivoxil (Ro 15-8075) with ascending oral doses in normal healthy volunteers.

Authors:  Y K Tam; J Kneer; U C Dubach; K Stoeckel
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

8.  Determination of cefetamet and its orally active ester, cefetamet pivoxyl, in biological fluids by high-performance liquid chromatography.

Authors:  R Wyss; F Bucheli
Journal:  J Chromatogr       Date:  1988-08-19

9.  In vitro activity of Ro 15-8074 and Ro 19-5247, two orally administered cephalosporin metabolites.

Authors:  R Wise; J M Andrews; L J Piddock
Journal:  Antimicrob Agents Chemother       Date:  1986-06       Impact factor: 5.191

  9 in total
  23 in total

1.  Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption.

Authors:  Justin J Wilkins; Radojka M Savic; Mats O Karlsson; Grant Langdon; Helen McIlleron; Goonaseelan Pillai; Peter J Smith; Ulrika S H Simonsson
Journal:  Antimicrob Agents Chemother       Date:  2008-04-07       Impact factor: 5.191

2.  A novel extravascular input function for the assessment of drug absorption in bioavailability studies.

Authors:  M Weiss
Journal:  Pharm Res       Date:  1996-10       Impact factor: 4.200

3.  Population Pharmacokinetic Modeling To Estimate the Contributions of Genetic and Nongenetic Factors to Efavirenz Disposition.

Authors:  Jason D Robarge; Ingrid F Metzger; Jessica Lu; Nancy Thong; Todd C Skaar; Zeruesenay Desta; Robert R Bies
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

4.  Population Pharmacokinetic Analysis of the Oral Absorption Process and Explaining Intra-Subject Variability in Plasma Exposures of Imatinib in Healthy Volunteers.

Authors:  Ali-Akbar Golabchifar; Saeed Rezaee; Nahid Mobarghei Dinan; Abbas Kebriaeezadeh; Mohammad-Reza Rouini
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-10       Impact factor: 2.441

5.  Population Pharmacokinetic Modeling of the Enterohepatic Recirculation of Fimasartan in Rats, Dogs, and Humans.

Authors:  Tae Hwan Kim; Soyoung Shin; Cornelia B Landersdorfer; Yong Ha Chi; Soo Heui Paik; Jayhyuk Myung; Rajbharan Yadav; Stefan Horkovics-Kovats; Jürgen B Bulitta; Beom Soo Shin
Journal:  AAPS J       Date:  2015-05-20       Impact factor: 4.009

6.  Population pharmacokinetic/pharmacodynamic model for the sedative effects of flibanserin in healthy volunteers.

Authors:  Iñaki F Trocóniz; Katja Boland; Alexander Staab
Journal:  Pharm Res       Date:  2012-01-05       Impact factor: 4.200

7.  A distributed delay approach for modeling delayed outcomes in pharmacokinetics and pharmacodynamics studies.

Authors:  Shuhua Hu; Michael Dunlavey; Serge Guzy; Nathan Teuscher
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-01-24       Impact factor: 2.745

8.  Population pharmacokinetic analysis of lanreotide Autogel in healthy subjects : evidence for injection interval of up to 2 months.

Authors:  Iñaki F Trocóniz; Josep-María Cendrós; Concepción Peraire; Joaquim Ramis; Maria J Garrido; Paolo F Boscani; Rosendo Obach
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

9.  Population pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator.

Authors:  Andreas Krause; Patrick Brossard; Daniele D'Ambrosio; Jasper Dingemanse
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-06-15       Impact factor: 2.745

Review 10.  Cefetamet pivoxil clinical pharmacokinetics.

Authors:  R A Blouin; K Stoeckel
Journal:  Clin Pharmacokinet       Date:  1993-09       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.